Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HLVX HilleVax	$2.07	$2.04	$1.34 ▼ $2.17	$103.79M	0.77	955,799 shs	344,238 shs
ONCY Oncolytics Biotech	$1.01	$0.96	$0.33 ▼ $1.53	$101.36M	1.09	835,578 shs	294,942 shs
RNTX Rein Therapeutics	$1.13 -1.7%	$1.39	$1.04 ▼ $4.40	$26.80M	1.31	67,059 shs	60,762 shs
TCRX TScan Therapeutics	$1.74 +2.4%	$1.68	$1.02 ▼ $6.23	$96.20M	0.99	254,189 shs	240,730 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HLVX HilleVax	0.00%	-0.48%	-1.90%	+11.29%	+3.50%
ONCY Oncolytics Biotech	0.00%	+7.41%	-18.55%	+141.40%	+6.33%
RNTX Rein Therapeutics	-1.74%	-2.16%	-18.12%	-44.88%	+112,999,900.00%
TCRX TScan Therapeutics	+2.35%	-3.87%	-5.95%	+26.09%	-70.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HLVX HilleVax	1.6117 of 5 stars	1.0	4.0	0.0	0.0	1.8	3.3	1.3
ONCY Oncolytics Biotech	1.7368 of 5 stars	3.4	3.0	0.0	0.0	2.0	0.0	0.0
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	3.2644 of 5 stars	3.5	5.0	0.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HLVX HilleVax	2.00	Hold	$2.00	-3.38% Downside
ONCY Oncolytics Biotech	2.80	Moderate Buy	$5.00	395.05% Upside
RNTX Rein Therapeutics	2.00	Hold	N/A	N/A
TCRX TScan Therapeutics	3.00	Buy	$7.80	348.28% Upside

Current Analyst Ratings Breakdown

Latest RNTX, ONCY, HLVX, and TCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	RNTX Rein Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/13/2025	ONCY Oncolytics Biotech	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/12/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/8/2025	HLVX HilleVax	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HLVX HilleVax	N/A	N/A	N/A	N/A	$2.95 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.04 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.44 per share	2.57	$0.13 per share	N/A
TCRX TScan Therapeutics	$2.82M	34.92	N/A	N/A	$3.12 per share	0.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HLVX HilleVax	-$147.27M	-$1.43	N/A	N/A	N/A	N/A	-34.29%	-28.50%	11/6/2025 (Estimated)
ONCY Oncolytics Biotech	-$23.14M	-$0.27	N/A	N/A	N/A	N/A	-438.11%	-143.90%	N/A
RNTX Rein Therapeutics	-$62.88M	-$2.69	N/A	N/A	N/A	N/A	-141.11%	-33.83%	N/A
TCRX TScan Therapeutics	-$127.50M	-$1.09	N/A	N/A	N/A	-1,964.88%	-63.33%	-40.19%	N/A

Latest RNTX, ONCY, HLVX, and TCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RNTX Rein Therapeutics	-$0.22	-$0.28	-$0.06	-$0.28	N/A	N/A
8/12/2025	Q2 2025	TCRX TScan Therapeutics	-$0.28	-$0.2848	-$0.0048	-$0.28	$1.31 million	$3.08 million
8/8/2025	Q2 2025	ONCY Oncolytics Biotech	-$0.11	-$0.05	+$0.06	-$0.05	N/A	N/A
8/6/2025	Q2 2025	HLVX HilleVax	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HLVX HilleVax	N/A	26.39	26.39
ONCY Oncolytics Biotech	N/A	2.88	2.88
RNTX Rein Therapeutics	N/A	0.86	1.39
TCRX TScan Therapeutics	0.18	7.06	7.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HLVX HilleVax	86.42%
ONCY Oncolytics Biotech	6.82%
RNTX Rein Therapeutics	90.89%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
HLVX HilleVax	24.90%
ONCY Oncolytics Biotech	0.10%
RNTX Rein Therapeutics	5.10%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
ONCY Oncolytics Biotech	30	100.36 million	100.26 million	Not Optionable
RNTX Rein Therapeutics	9	23.31 million	22.12 million	N/A
TCRX TScan Therapeutics	100	56.59 million	54.13 million	Not Optionable

RNTX, ONCY, HLVX, and TCRX Headlines

Recent News About These Companies

Tocqueville Asset Management L.P. Sells 233,870 Shares of TScan Therapeutics, Inc. $TCRX

August 21 at 4:34 AM | marketbeat.com

What is Lifesci Capital's Forecast for TCRX FY2025 Earnings?

August 19 at 2:29 AM | marketbeat.com

Lifesci Capital Issues Pessimistic Outlook for TCRX Earnings

August 19 at 2:17 AM | americanbankingnews.com

HC Wainwright Has Optimistic Outlook of TCRX FY2025 Earnings

August 17, 2025 | marketbeat.com

What is Lifesci Capital's Forecast for TCRX Q3 Earnings?

August 17, 2025 | marketbeat.com

Wedbush Cuts Earnings Estimates for TScan Therapeutics

August 17, 2025 | marketbeat.com

HC Wainwright Expects Higher Earnings for TScan Therapeutics

August 17, 2025 | americanbankingnews.com

Q3 EPS Estimates for TScan Therapeutics Cut by Wedbush

August 17, 2025 | americanbankingnews.com

Research Analysts Set Expectations for TCRX Q3 Earnings

August 16, 2025 | americanbankingnews.com

TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings Results

August 15, 2025 | marketbeat.com

TScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash Wisely

August 15, 2025 | finance.yahoo.com

Wedbush Reaffirms Outperform Rating for TScan Therapeutics (NASDAQ:TCRX)

August 14, 2025 | americanbankingnews.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

August 13, 2025 | marketbeat.com

TScan Therapeutics Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

TScan Therapeutics reports Q2 EPS (28c), consensus (32c)

August 12, 2025 | msn.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2025 | zacks.com

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | globenewswire.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

August 5, 2025 | marketbeat.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by Brokerages

August 3, 2025 | marketbeat.com

TScan Therapeutics Elects New Directors at Annual Meeting

July 27, 2025 | theglobeandmail.com

One TScan Therapeutics Insider Raised Stake By 18% In Previous Year

July 19, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ONCY, HLVX, and TCRX Company Descriptions

HilleVax NASDAQ:HLVX

$2.06 0.00 (-0.24%)

As of 08/21/2025 04:00 PM Eastern

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Oncolytics Biotech NASDAQ:ONCY

$1.01 0.00 (0.00%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$1.01 +0.00 (+0.50%)

As of 08/21/2025 04:34 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Rein Therapeutics NASDAQ:RNTX

$1.13 -0.02 (-1.74%)

As of 08/21/2025 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

TScan Therapeutics NASDAQ:TCRX

$1.74 +0.04 (+2.35%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$1.75 +0.01 (+0.57%)

As of 08/21/2025 07:30 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time